Lexeo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lexeo Therapeutics, Inc. - overview
Established
2018
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2018 by Ronald G. Crystal, Lexeo Therapeutics, Inc. is a biotechnology company that develops adeno-associated virus (AAV)-mediated therapies. In May 2025, Lexeo Therapeutics, Inc.
raised USD 80 million in PIPE funding co-led by Frazier Group and Janus Henderson Investors. The company trades on NASDAQ under the ticker symbol LXEO. Lexeo Therapeutics develops and provides AAV (adeno-associated virus)-mediated therapies to treat patients with genetic diseases. The company's pipeline includes three clinical-stage gene therapy programs in monogenic diseases and up to 15 potential additional AAV gene therapy programs in monogenic and acquired diseases.
The company’s preclinical pipeline includes monogenic diseases as well as hereditary and acquired diseases. The company will use the May 2025 funding to accelerate the development of its cardiovascular drugs.
Current Investors
Janus Henderson Investors, Frazier VC, Alexandria Venture Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.lexeotx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Lexeo Therapeutics, Inc. - timeline of key events
Lexeo Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Revenue (USD) | 654,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (59,364,000) | - | - | - |
| Operating Income (USD) | (60,509,000) | - | - | - |
| Operating Margin | (9252.1%) | - | - | - |
| % EBITDA Margin | (9077.1%) | - | - | - |
| NET Income (USD) | (59,277,000) | - | - | - |
| % Net Margin | (9063.8%) | - | - | - |
Lexeo Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Lexeo Therapeutics, Inc. | - | ||||||||
| PIPE | Completed | Lexeo Therapeutics, Inc. | - |
Displaying 1 - 2 of 2
Lexeo Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.